News

Ophthalmology Times13d
Valorum Biologics to commercialize Formycon’s Eylea Biosimilar FYB203 in US and Canada
FYB203 has been approved by the US FDA and UK Medicines and Healthcare products Regulatory Agency for the treatment ...
Business Insider5mon
Teva Announces Collaboration to Commercialize Formycon’s Biosimilar Candidate to Eylea® (aflibercept) in major parts of Europe and in Israel - Markets Insider
Klinge Biopharma GmbH (Klinge) holds the exclusive global commercialization rights for FYB203, Formycon's biosimilar candidate to Eylea ® 1 Agreement builds on the proven and successful ...
Business Insider5mon
EQS-News: Teva becomes strategic commercialization partner for Formycon’s biosimilar candidate FYB203 (Eylea®/ aflibercept) in major parts of Europe and Israel - Markets Insider
Teva becomes strategic commercialization partner for Formycon’s biosimilar candidate FYB203 (Eylea®/ aflibercept) in major parts of Europe and Israel 13.01.2025 / 07:00 CET/CEST The issuer is ...
PharmiWeb1y
Formycon announces EMA submission for FYB203, a biosimilar candidate to Eylea® (Aflibercept)
EQS-News: Formycon AG / Key word(s): Regulatory AdmissionFormycon announces EMA submission for FYB203, a biosimilar candidate to Eylea® (Aflibercept) 27.11.2023 / 07:30 CET/CESTThe issuer is solely ...
Mena FN5mon
Formycon And Fresenius Kabi Announce MHRA Approval For FYB202/Otulfi® (Ustekinumab), A Biosimilar To Stelara® - MENAFN.COM
Planegg-Martinsried, Germany - Formycon AG (FSE: FYB, Prime Standard,“Formycon”) and its commercialization partner Fresenius Kabi announce that the UK Medicines and Healthcare products ...
Yahoo Finance5mon
Teva Announces Collaboration to Commercialize Formycon’s Biosimilar Candidate to Eylea® (aflibercept) in major parts of Europe and in Israel - Yahoo Finance
Klinge Biopharma GmbH (Klinge) holds the exclusive global commercialization rights for FYB203, Formycon's biosimilar candidate to Eylea®1Agreement builds on the proven and successful ...
Nasdaq5mon
Teva Announces Collaboration to Commercialize Formycon’s Biosimilar Candidate to Eylea® (aflibercept) in major parts of Europe and in Israel - Nasdaq
Klinge Biopharma GmbH holds the exclusive global commercialization rights for FYB203, Formycon's biosimilar candidate to Eylea ® 1 Agreement builds on the proven and successful collaboration of ...